CLINUVEL Receives EMA Approval for SCENESSE Phase III Vitiligo Trial Starting 2026

Key Takeaways

• EMA provides final scientific advice for CLINUVEL’s pivotal Phase III vitiligo study using SCENESSE
• Study will compare SCENESSE plus NB-UVB therapy versus NB-UVB monotherapy in 300 patients
• CUV107 trial scheduled to commence in second half of 2026 following EMA’s ‘totality of evidence’ approach

---

CLINUVEL PHARMACEUTICALS LTD announced April 24, 2026, that the European Medicines Agency (EMA) has provided final scientific advice for its pivotal Phase III vitiligo study, marking a significant regulatory milestone for the company’s SCENESSE® (afamelanotide) treatment program.

Study Design and Regulatory Framework

The CUV107 study will enroll 300 patients to compare SCENESSE combined with narrowband ultraviolet B (NB-UVB) phototherapy against NB-UVB monotherapy alone. The EMA emphasized its “totality of evidence” approach, agreeing to central photographic review and validated disease assessment tools for the trial.

IntelligenceRegulatory Impact▾

EMA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Clinical Significance for Vitiligo Treatment

Vitiligo affects approximately 1% of the global population, causing white patches on the skin due to loss of melanocytes. Current treatment options remain limited, making SCENESSE’s potential combination therapy particularly significant for patients seeking improved repigmentation outcomes.

SCENESSE, already approved in Europe for erythropoietic protoporphyria (EPP), works by stimulating melanin production. The combination with NB-UVB therapy could potentially enhance treatment efficacy compared to phototherapy alone.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Timeline

The regulatory green light positions CLINUVEL to advance its dermatology pipeline beyond rare photodermatoses. With the study commencing in the second half of 2026, results could be available by 2028-2029, potentially expanding SCENESSE’s market reach significantly.

The vitiligo therapeutics market, valued at over $1 billion globally, represents a substantial commercial opportunity. Success in this indication could transform SCENESSE from a niche rare disease treatment into a broader dermatology asset.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Next Steps

CLINUVEL will now focus on study site selection, patient recruitment strategies, and finalizing operational aspects of the international trial. The company’s established European commercial infrastructure for SCENESSE provides advantages for potential future commercialization in vitiligo.

---

Frequently Asked Questions

What does this mean for vitiligo patients?

This approval allows CLINUVEL to test whether combining SCENESSE with light therapy provides better skin repigmentation than current standard treatment alone, potentially offering improved outcomes for vitiligo patients.

When will SCENESSE be available for vitiligo treatment?

The Phase III trial starts in late 2026 and will take several years to complete. If successful, regulatory approval and commercial availability would likely occur around 2029-2030 at the earliest.

How does SCENESSE compare to existing vitiligo treatments?

SCENESSE stimulates melanin production and would be used alongside standard NB-UVB light therapy. The trial will determine if this combination provides superior repigmentation compared to light therapy alone, which is currently the standard of care.

Related coverage

• Hayes Receives 2026 ESMO Breast Cancer Award: Key Insights
• Karyopharm's Selinexor Plus Ruxolitinib SENTRY Trial Data to be Presented at EHA 2026
• KRX IR Reference : Executive Summary Plan for SCD NDR (ENG, Jun 2026)